Aspect Biosystems is a biotechnology company pioneering the development of Bioprinted Tissue Therapeutics (BTTs) to transform how we treat some of the most elusive diseases. Aspect’s BTTs are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of BTTs across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect's pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity.
Company Details
- Employees
- 119
- Founded
- -
- Address
- 2131 Manitoba St, Vancouver,british Columbia V5y 0n7,canada
- Phone
- 604 263 0502
- in****@****ems.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.aspectbiosystems.com
- HQ
- Vancouver, British Columbia
Aspect Biosystems Questions
Aspect Biosystems's helpline number is 604 263 0502
Aspect Biosystems's website is http://www.aspectbiosystems.com
Aspect Biosystems's LinkedIn profile is https://ca.linkedin.com/company/aspect-biosystems
Aspect Biosystems has
119 employees.
View email and phone details for 119
employees at Aspect Biosystems.
Aspect Biosystems's industry is
Biotechnology Research
Aspect Biosystems's top competitors are
Terray Therapeutics,
City Therapeutics,
Stemcell Technologies,
Xenon Pharmaceuticals Inc.,
Acuitas Therapeutics,
Abcellera,
Atalanta Therapeutics,
Kailera Therapeutics,
Admare Bioinnovations,
Zymeworks Inc..
Aspect Biosystems's support email address is info@aspectbiosystems.com
Aspect Biosystems's categories are Biotechnology Research
Aspect Biosystems's founding year is 2013
